- Home
- ACAD vs KFY Comparison
ACAD vs KFY Comparison
Compare ACAD & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- KFY
- Stock Information
- Founded
- ACAD 1993
- KFY 1969
- Country
- ACAD United States
- KFY United States
- Employees
- ACAD N/A
- KFY N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- KFY Diversified Commercial Services
- Sector
- ACAD Health Care
- KFY Consumer Discretionary
- Exchange
- ACAD Nasdaq
- KFY Nasdaq
- Market Cap
- ACAD 4.3B
- KFY 3.9B
- IPO Year
- ACAD 2004
- KFY 1999
- Fundamental
- Price
- ACAD $23.61
- KFY $72.31
- Analyst Decision
- ACAD Buy
- KFY Buy
- Analyst Count
- ACAD 21
- KFY 2
- Target Price
- ACAD $29.30
- KFY $80.00
- AVG Volume (30 Days)
- ACAD 1.9M
- KFY 411.3K
- Earning Date
- ACAD 11-05-2025
- KFY 09-09-2025
- Dividend Yield
- ACAD N/A
- KFY 2.64%
- EPS Growth
- ACAD 615.00
- KFY 33.45
- EPS
- ACAD 1.33
- KFY 4.69
- Revenue
- ACAD $1,018,885,000.00
- KFY $2,763,755,000.00
- Revenue This Year
- ACAD $14.01
- KFY $3.15
- Revenue Next Year
- ACAD $11.72
- KFY $4.79
- P/E Ratio
- ACAD $17.82
- KFY $15.53
- Revenue Growth
- ACAD 14.41
- KFY 0.93
- 52 Week Low
- ACAD $13.40
- KFY $59.23
- 52 Week High
- ACAD $26.65
- KFY $80.64
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- KFY 45.80
- Support Level
- ACAD $23.70
- KFY $71.92
- Resistance Level
- ACAD $25.90
- KFY $75.19
- Average True Range (ATR)
- ACAD 0.74
- KFY 1.83
- MACD
- ACAD -0.33
- KFY -0.19
- Stochastic Oscillator
- ACAD 8.16
- KFY 5.93
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About KFY Korn Ferry
Korn Ferry is a United States-based firm engaged in organizational consulting and management recruitment that helps clients fill mid- to high-level management positions. The company's segment includes Consulting; Digital; Executive Search; Professional Search & Interim; and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The consulting segment aligns organizational structure, culture, performance, development, and people to drive sustainable growth by addressing four fundamental organizational and talent needs. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.